Researchers Seek Ways To Add Speed, Economy, And Flexibility To Process Of Producing Drugs

Information retailers document on tales associated with pharmaceutical pricing.

Fast, Nimble, And On Demand: The Pursuit Of A New Way To Mass Produce Medicines

As of late there’s necessarily one fashion for drug manufacturing: make up to imaginable. However J. Christopher Love, a professor of chemical engineering on the Massachusetts Institute of Generation, has spent the final 5 years pursuing a special imaginative and prescient: a desktop drug production procedure that may be rapid and nimble sufficient to lend a hand battle a small illness outbreak, deal with an extraordinary most cancers, or change a unprecedented enzyme. He’s now not there but, however in a paper revealed this week in Nature Biotechnology, Love and his colleagues confirmed that they are able to produce hundreds of doses of clinical-quality biologically primarily based medication in about 3 days. (Weintraub, 10/four)

Ohio Medicaid Examines A Curious PBM Relationship

In fresh months, controversy over the Ohio Medicaid program has supplied a unprecedented window into one of the crucial charges paid to pharmacy get advantages managers and the next impact on prescription drug prices. Now, an audit unearths a brand new twist: A controlled care plan that shriveled with the state program accrued $20 million thru a curious association that has raised worry amongst state officers. (Silverman, 10/five)

Milwaukee Journal Sentinel:
Evers Proposes To Fine Pharmaceutical Firms Over Price Hikes

Democratic candidate for governor Tony Evers would search to decrease prescription drug costs by way of growing a brand new state board that may have the authority to check value hikes and impose fines on drug makers for “over the top” will increase. The plan Evers launched Monday additionally will require drug corporations to justify huge value will increase, make the state’s prescription drug program for seniors quilt flu photographs and make allowance uploading medication from Canada. (Beck, 10/eight)

Columbus Dispatch:
Taxpayers May Be Paying Twice For The Same Medicaid Drug Services

The group that came upon that Ohio taxpayers had been overcharged as much as $186 million for Medicaid pharmaceuticals final yr has exposed an extra $20 million that would possibly were wasted to fund products and services for which taxpayers already had been paying. And state Medicaid officers first of all didn’t need that knowledge made public. (Schladen and Sullivan, 10/7)

Perrigo Taps Tobacco Executive As CEO In Shift From Drugs

Kessler, 59, is the previous CEO of Lorillard Tobacco Co. He replaces Uwe Roehrhoff, who was once appointed president and CEO in January to switch John Hendrickson. Perrigo has been seeking to flip itself round after a 16 p.c decline within the stocks up to now 12 months. It’s within the means of setting apart its pharmaceuticals trade and refocusing on client well being merchandise corresponding to an over the counter model of heartburn drug Nexium. The separation shall be finished by way of year-end, and choices come with a sale or merger. (Hopkins, 10/eight)

The Wall Street Journal:
Pfizer Prepares For CEO Transition With Executive Suite Changes

Pfizer Inc. assigned new management roles and jobs to a spread of best executives, because the drugmaker prepares for Albert Bourla to start out his tenure as leader govt in January. Previous this month, Pfizer mentioned its CEO, Ian Learn, would depart the process after 8 years to make manner for Mr. Bourla, who lately serves as leader running officer. (Maidenberg, 10/nine)

This is a part of the KHN Morning Briefing, a abstract of well being coverage protection from main information organizations. Join an e mail subscription.

About the Author

Leave a Reply

Your email address will not be published. Required fields are marked *